Eli Lilly Posts 56% Revenue Growth in Q1 2026 as GLP-1 Drugs Rewrite the Pharmaceutical Playbook
Eli Lilly reported first-quarter 2026 results that exceeded expectations on every meaningful metric, sending its stock up nearly 7% — the company’s biggest single-day gain in three months. The results are powered almost entirely by two drugs: Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity).
The Numbers
| Metric | Q1 2026 | Q1 2025 | YoY Change |
|---|---|---|---|
| Total Revenue | $19.8B | $12.7B | +56% |
| Mounjaro (Global) | $8.7B | $3.9B | +125% |
| Zepbound (US) | $4.1B | $2.3B | +79% |
| Combined GLP-1 | $12.8B | $6.1B | +110% |
| US Revenue | $12.1B | $8.5B | +43% |
| International Revenue | $7.7B | $4.3B | +81% |
The combined GLP-1 revenue of $12.8 billion in a single quarter means Mounjaro and Zepbound alone are generating revenue at an annualized rate of over $50 billion — a figure that would make them collectively one of the largest pharmaceutical franchises in history.
What’s Driving the Numbers
Mounjaro: $8.7 Billion and Still Accelerating
Mounjaro’s 125% year-over-year growth to $8.7 billion reflects both continued US market penetration and accelerating international launches. The drug, approved for type 2 diabetes, is increasingly prescribed by physicians as a first-line treatment due to its superior efficacy in both glucose control and weight reduction compared to older GLP-1 receptor agonists.
The international growth is particularly notable: revenue outside the US increased 81%, driven by launches in major European markets and Japan. Lilly has been expanding manufacturing capacity to meet demand that has historically outstripped supply.
Zepbound: The Obesity Market Takes Shape
Zepbound’s US revenue of $4.1 billion (+79% YoY) represents the continued ramp of the obesity indication. Unlike Mounjaro, which benefits from established diabetes treatment pathways and insurance coverage, Zepbound has had to build its market partly through cash-pay patients and expanding payer coverage.
The growth trajectory suggests that insurance coverage for obesity treatment is broadening, a structural tailwind that could sustain Zepbound’s growth for several years as more employers and insurers add weight management to their formularies.
Volume vs. Price
Lilly disclosed that worldwide revenue growth was driven by a 65% increase in volume, partially offset by a 13% decrease from lower realized prices. This dynamic reflects the company’s strategy of prioritizing access and volume over unit pricing — accepting lower average selling prices in exchange for broader market penetration, particularly internationally where government price negotiations apply.
Raised Guidance
Lilly raised its full-year 2026 guidance on both the top and bottom lines:
| Metric | New Guidance | Previous Guidance | Change |
|---|---|---|---|
| Revenue | $82-85B | $80-83B | +$2B |
| Adjusted EPS | $35.50-37.00 | $33.50-35.00 | +$2.00 |
The raise signals management’s confidence that the Q1 demand trends are sustainable through the balance of the year. If Lilly hits the midpoint of its new revenue guidance ($83.5B), it would represent approximately 45% growth over full-year 2025.
The Bigger Picture: GLP-1 as a Platform
Lilly’s results underscore a structural shift in pharmaceutical economics. The GLP-1 drug class — which includes both Lilly’s tirzepatide products and Novo Nordisk’s competing semaglutide franchise (Ozempic, Wegovy) — is creating a new category of blockbuster drug that operates at a scale previously unseen in the industry.
At an annualized run rate of $50+ billion, Lilly’s GLP-1 franchise alone generates more revenue than most entire pharmaceutical companies. The potential market expansion into adjacent indications — heart failure, kidney disease, sleep apnea, and NASH/liver disease — could extend the growth runway well beyond the current diabetes and obesity labels.
Stock Reaction and Valuation
Eli Lilly shares spiked nearly 7% on the results, reflecting both the earnings beat and the guidance raise. The stock has been one of the top performers in the S&P 500 over the past two years, driven by the GLP-1 thesis.
At current levels, Lilly trades at a premium to the broader pharma sector, but the growth rate differential justifies it: 56% revenue growth in a sector where mid-single-digit growth is considered strong.
What to Watch Next
The competitive landscape remains the key variable. Novo Nordisk reports results later this quarter, and the comparison between Mounjaro/Zepbound and Ozempic/Wegovy will continue to shape investor sentiment. Additionally, potential FDA label expansions for tirzepatide in cardiovascular and renal indications could provide catalysts in the second half of 2026.
For the broader market, Lilly’s results confirm that the Big Tech earnings week was not the only source of positive earnings surprises — healthcare is producing its own growth story that is largely independent of the AI narrative driving tech valuations.
Sources: Eli Lilly Q1 2026 press release (investor.lilly.com), CNBC, Quartz, Benzinga, Invezz.